Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359231221907 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 18.01.2024. Verfasst von Chih-Hao Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chang Gung Medical Foundation.
Abstract (Originalsprache)
Background
Lung cancers are common worldwide. First-line targeted therapy and chemotherapy are both standard treatments in the current guidelines. With the development of new anticancer therapy, the lifespan of patients with late-stage lung cancer has increased. Cardiovascular events can occur during cancer treatment. This observational study aimed to report the incidence of major adverse cardiovascular events (MACE) after cancer treatment using real-world data.
Objectives
Patients diagnosed with advanced-stage lung cancer between January 2011 and December 2017 were enrolled. Data were collected from the Chang Gung Research Database (CGRD).
Design
Retrospective cohort study.
Methods
Baseline characteristics, clinical stages, pathologies, and outcomes were retrieved from the CGRD.
Results
We identified 4406 patients with advanced lung cancer, of whom 2197 received first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and 2209 received first-line platinum-based chemotherapy. Most patients in the first-line EGFR-TKI group were never-smokers (74.9%), whereas those in the first-line chemotherapy group were ever-smokers (66.0%). The incidence of MACE was not significantly different between the two groups (12.0% versus 11.9%, p = 0.910). However, the incidence of ischemic stroke was higher in the first-line EGFR-TKI group than in the first-line chemotherapy group (3.9% versus 1.9%, p < 0.001).
Conclusion
MACEs are common in patients with advanced-stage lung cancer during treatment. The incidence of MACE was similar between the first-line EGFR-TKI therapy and first-line chemotherapy groups. Although more patients in the EGFR-TKI group were female and never-smokers, the risk of ischemic stroke was higher in patients who received first-line EGFR-TKI therapy than in those who received first-line chemotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
- Department of Thoracic Medicine, Chang Gung Memorial Hospital Linkou Branch, 5, Fuxing Street, Guishan District, Taoyuan City 333, Taiwan.
- Department of Thoracic Medicine, Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan.
- Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital Chiayi Branch, Chiayi County, Taiwan.
- Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan.
ORCID-Profile: Chih-Hao Chang, Meng-Hung Lin, Chung-Shu Lee, Jason Chia-Hsun Hsieh
Förderung
- Chang Gung Medical Foundation
Zitieren
APA
Chang, C. H., Huang, S. H., Huang, H. Y., Lin, M. H., Lee, C. S., Lee, H. F., Hsieh, J. C., & Cheng, C. Y. (2024). Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231221907
Vancouver
Chang CH, Huang SH, Huang HY, Lin MH, Lee CS, Lee HF, et al. Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231221907
BibTeX
@article{Chang2024,
author = {Chang, Chih-Hao and Huang, Shih-Hao and Huang, Hung-Yu and Lin, Meng-Hung and Lee, Chung-Shu and Lee, Hsin-Fu and Hsieh, Jason Chia-Hsun and Cheng, Chun-Yu},
title = {Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359231221907}
}
EUVIMED